Document Detail


[New evidences on the use of aldosterone receptor antagonists in left ventricular dysfunction. From myocardial infarction to heart failure].
MedLine Citation:
PMID:  23196683     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Heart failure and myocardial infarction result in considerable consumption of healthcare resources. Therefore, there is interest in the availability of drug therapies that can favorably modify their prognosis in the post-acute phase, reducing mortality and rehospitalization rates. Aldosterone antagonists represent a class of drugs which offer advantages in these settings, in addition to those obtained with beta-blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, even though attention should be drawn to their potential adverse effects. In particular, eplerenone exhibits a better safety profile than spironolactone. Since it has very little affinity for glucocorticoid, androgen and progesterone receptors, eplerenone has less antiandrogenic and progestagenic effects, resulting in a lower incidence of gynecomastia. The EPHESUS study showed that eplerenone can reduce mortality in the short and long term and the rate of new hospitalizations after a myocardial infarction complicated by heart failure. In addition, in the EMPHASIS-HF study eplerenone reduced cardiovascular mortality and hospitalizations after mild heart failure (NYHA class IIa). Despite these important results, which confirmed those obtained with spironolactone in severe heart failure in the RALES study, aldosterone antagonists are still underutilized. In particular, eplerenone is not yet available in Italy, although it is recommended by the latest European Society of Cardiology guidelines.
Authors:
Cesare Greco; Gabriele Castelli; Filippo Crea; Antonello Gavazzi; Gian Franco Gensini; Marino Scherillo; Gianfranco Sinagra
Publication Detail:
Type:  English Abstract; Journal Article    
Journal Detail:
Title:  Giornale italiano di cardiologia (2006)     Volume:  13     ISSN:  1827-6806     ISO Abbreviation:  G Ital Cardiol (Rome)     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-30     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101263411     Medline TA:  G Ital Cardiol (Rome)     Country:  Italy    
Other Details:
Languages:  ita     Pagination:  809-16     Citation Subset:  IM    
Vernacular Title:
Nuove evidenze sull'impiego degli antialdosteronici nella disfunzione ventricolare sinistra: spironolattone ed eplerenone. Dal postinfarto allo scompenso cardiaco.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  [Left ventricular ejection fraction: pathophysiological aspects and intrinsic limitations].
Next Document:  [Proton pump inhibitors and clopidogrel: an association to avoid?].